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Abstract
Background: The purpose of this study was to determine the direct medical US cost of managing
multiple sclerosis relapses.
Methods: Direct data analysis and cost modeling were employed to derive typical resource use
profiles and costs in 2002 US dollars, from the perspective of a third-party payer responsible for
comprehensive health-care. The location and scope of health care services provided over a 90-day
period were used to define three levels of relapse management. Hospitalization and resulting
subsequent care was defined as high intensity management. A medium level of intervention was
defined as either use of the emergency room, an observational unit, or administration of acute
treatments, such as intravenous methylprednisolone in an outpatient or home setting. The lowest
intensity of care comprised physician office visits and symptom-related medications. Data were
obtained from many sources including all payer inpatient, ambulatory and emergency room
databases from several states, fee schedules, government reports, and literature. All charges were
adjusted using cost-to-charge ratios.
Results: Average cost per person for high management level was $12,870, based on analysis of
4,634 hospital cases (mean age 48 years, 73% female). Hospital care comprised 71% of that cost.
At discharge, 36% required inpatient sub-acute care, rehabilitation or home care. The typical cost
per moderate episode was $1,847 and mild episode $243.
Conclusions: Management strategies leading to a reduction in the frequency and severity of a
relapse, less reliance on inpatient care, or increased access to steroid infusions in the home, would
have a substantial impact on the economic consequences of managing relapses.
Background
Although the exact number of people with multiple scle-
rosis (MS) is not known in the United States (US), pub-
lished estimates put the number at between 250,000 to
350,000 [1]. The majority of patients initially have a form
of MS described as "relapsing-remitting", which manifests
as a series of exacerbations followed by periods of partial
or complete remission, and 30–50% of those will have
progressive symptoms within the first ten years [2].
Relapse rates vary widely (0.1 to 1 attack per year), and
patients with higher relapse rates in the first two years
after onset of symptoms have been observed to be at
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greater risk of more rapid progression to a severe level of
disability [3]. Most people experience their first symptoms
between the ages of 20 and 40 years; therefore, this disease
may have a substantial impact over many years on their
health, quality of life, productivity and employment [1,4].
The annual cost of MS in the US has been estimated to be
$2.5 billion [1].
In a clinical area where relief of symptoms has been the
mainstay of management, the development of new dis-
ease modifying drugs for MS in recent years has provided
hope for patients due to their important clinical benefits.
Data published by the National Consortium of Multiple
Sclerosis Centers in 2000, [5] showed that 78% of patients
questioned reported ever taking a disease modifying drug
and 67% of patients were currently taking one. Clearly,
these agents have been embraced as a therapy for relaps-
ing-remitting MS and in a cost conscious clinical environ-
ment concerned with limited health care dollars their
impact should be examined not only in clinical terms
such as reducing relapse rates, or severity or modifying the
progression of the disease, but also with an understanding
of their economic consequences. Medical decision-mak-
ing in managed care organizations (MCO) and elsewhere
should not take place in an economic vacuum. To facili-
tate these decisions, it is necessary to have current esti-
mates of the direct medical costs related to managing MS.
As there is little published in the literature relating to the
direct medical cost of relapse in the U.S, this paper focuses
on providing a key piece of the economic puzzle for
relapsing-remitting MS – the cost of managing an episode
of relapse.
Methods
Study Design
The goal of this analysis is to provide estimates of the
direct medical costs of managing a relapse in multiple
sclerosis. These costs are meant to reflect the economic
value of the resources consumed, regardless of who actu-
ally pays for them (for example, Medicare, Medicaid or a
commercial insurer). Thus, they do not take into account
adjustments made in the multi-payer US system, such as
differences in coverage of medications, co-payments,
reimbursement rates or volume discounts.
The cost estimates were developed to provide a compre-
hensive picture of the direct medical costs associated with
managing a relapse of MS. The range of health care serv-
ices used to manage a relapse will consequently reflect the
severity of the initial signs and symptoms. When patients
have a relapse, they can experience a diverse range of
symptoms of neurological dysfunction, which eventually
may resolve partially, completely, or stabilize [6]. The
severity of symptoms experienced during a relapse varies
widely and may include sensory loss, optical neuritis,
weakness of the limbs leading to fatigue, disturbance of
gait, loss of dexterity, and paraesthesias [6]. The duration
of a relapse episode also varies and may last up to several
months[6].
Symptoms associated with a relapse can be treated in a
number of ways and at different levels of formal care.
Therefore, for the purpose of this analysis, the place where
health care was delivered and scope of services provided
was used to define three levels of management of a
relapse. The health care services and their associated costs
used during a relapse episode, defined as a 90-day period
for this analysis based on information from the literature
[7], were estimated for each of the three management lev-
els. Hospitalization was defined as high intensity manage-
ment of a relapse. A medium level of intervention was
considered to be either use of the emergency room (ER),
or an observational unit, or administration of acute treat-
ments requiring formal intervention, such as intravenous
(IV) methylprednisolone given in an outpatient or home
setting. The lowest intensity of care provided for a relapse
is comprised of physician office visits and symptom-
related medications. The major cost centers included in
the profiles for each management level are indicated in
Figure 1.
As there is no single data source available that provides all
of the information required to derive the cost of a relapse,
it was necessary to gather data from a variety of sources
and employ a combination of direct data analysis and cost
modeling based on typical clinical management profiles.
A resource use profile for each management level was
developed by identifying the health care goods and serv-
ices relevant to a relapse, quantifying the frequency of use
and proportion of users for each item included in the pro-
file, and applying a unit cost to each resource used.
Data Sources
Hospital inpatient care
Inpatient resource use and costs were derived from an
analysis of all payer, 1999 discharge data from five states
representing different areas of the US (California, Florida,
Maryland, Massachusetts, Washington) [8–12]. These
databases include demographic, clinical, and economic
data for discharges from 980 hospitals. Patients diagnosed
with MS were identified in each database (principal or sec-
ondary diagnosis International Classification of Diseases
code, ICD-9 code: 340). When MS was coded as a second-
ary diagnosis, only those cases with a principal diagnosis
of a condition or symptom that could be associated with
a relapse were included in the analyses. All cases with a
principal diagnosis of depression were excluded from the
analysis.BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/17
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Hospital costs include all accommodations, all ancillary
and physician-related services. ER costs are included for
those who used that service prior to admission. Inpatient
physician care profiles were developed for cases of MS
from the information in the five hospital discharge data-
bases. These profiles were developed based on the
recorded length of stay (LOS), procedure codes, special
care unit and ER use, surgical and anesthesia activities,
consultations and other physician-related database ele-
ments. For patients 65 years and older, the 2002 Medicare
national physician fee schedules [13] were applied to esti-
mate the cost of inpatient and outpatient physician-
related services. For younger patients, the Medicare fees
were adjusted with ratios derived from published fees for
common types of insurers (i.e. Medicaid, preferred pro-
vider organizations, and indemnity plans) [14,15]. This
methodology was applied to all physicians and test costs
at all management levels in this analysis.
Overview of health care services and resource use profiles used to define management levels during a 90-day relapse episode Figure 1
Health Care Services in Resource Use Profiles
Low Intensity Episode
# Initial Contact: 
• Usual care MD
# Symptom-Related  Meds
# Follow-up Office Visits
High Intensity Episode
# Initial Contact:
• Usual care MD
• Emergency Room
# Hospital Admission
• All acommodations
• All ancillaries
• Physician care
# Post-Discharge Services
• Outpatient follow-up 
• Rehabilitation
• Home health care 
• Skilled nursing facility
• Short stay nursing home care
• Hospital readmission
 within 30 days 
Moderate Intensity Episode
# Initial Contact:
• Usual care MD
• Emergency Room
# IV Methylprednisolone
• Hospital day case
• Home administration
# Symptom-Related Meds
# Follow-up Office Visits
# Consults
# Therapist
        • Physical
• Occupational
        • Speech
Relapse Cost Components 
Figure 1 Overview of health care services and resource use profiles used to define 
management levels during a 90-day relapse episode
(Abbreviation: IV= intravenous, MD = medical doctor)BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/17
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Post-acute care
Health care service use does not end upon discharge from
the hospital; therefore, care after hospitalization was fac-
tored into the management profiles for those who
required hospital level of care. The location of care (i.e.,
discharged home to outpatient care or with home health
care services, transferred to rehabilitation units, skilled
nursing facilities (SNF), or medically supervised nursing
homes for short-term care) following discharge was deter-
mined using disposition status data from the five states. In
addition, re-admission to the acute care hospital for a sim-
ilar problem within one month of the index admission
was considered to be a component of the costs of the
relapse episode. Readmission patterns were analyzed
using the data from the Massachusetts database, which
includes unique patient identifiers [10].
The length of stay and costs of inpatient rehabilitation
care were estimated from the same five state databases.
The cases were selected where the primary reason for
admission was rehabilitation and MS was coded as a sec-
ondary diagnosis. The disposition status at discharge from
inpatient rehabilitation was examined to determine if the
patient returned home, required home health care service
or was transferred to a skilled nursing facility. These data
were supplemented with information published by the
New Hampshire Hospital Association on patients admit-
ted with MS to rehabilitation facilities for the years 1996
through 1999 [16–19]. Medicare and Medicaid data pub-
lished by the Center for Medicare and Medicaid Services
(CMS) were used to establish the LOS, visit rate and unit
cost information for SNF care and home health care serv-
ices [20]. Nursing home per diem costs were established
by analyzing statewide data for patients with a primary
diagnosis of MS when admitted to long term care facilities
in Minnesota [21]. The Minnesota costs were adjusted to
national values using published nursing home per diem
costs [22]. The rate of physician visits to the nursing home
was estimated from medical literature [23].
Emergency Room and Observation Unit Visits
Estimates of resource use and cost data were obtained
from the 1999 Utah all payer ER database [24] and the
1999 Massachusetts Observation Unit database [25]. The
criteria used for selecting MS cases were the same as those
used for inpatient care.
Outpatient Care
Data from the 1999 Florida Medicaid ambulatory care
database [26] and the National Ambulatory Care Survey
(NAMCS) [27–29], as well as published Medicare and
Medicaid data [13,14] and published literature [30–34]
were examined and used to develop the outpatient pro-
files and management costs. In addition, NAMCS data
from the 1997, 1998, and 1999 databases [27–29,35]
were pooled and weighted by patient visit weights as
described in the National Ambulatory Medical Care Sur-
vey Data File Documentation [36]. The NAMCS is a prob-
ability sample where data are derived from a randomly
selected group of office-based physicians [37]. In those
with a coded diagnosis of MS, the general reason for the
physician encounter was used to discern a routine visit for
a chronic condition (assumed to be a remission-related
usual care visit) from a visit to the physician for an acute
problem, which was assumed to be a relapse-related visit.
The disposition status at the end of the visit was used to
determine whether patients were scheduled for a follow-
up visit, referred to a consultant, not scheduled to return
or those who should return only if necessary.
Basic laboratory tests such as a complete blood count
(CBC) and basic metabolic profile were included in the
cost of the initial comprehensive assessment visit with the
usual care physician. The proportions of patients receiving
other tests were estimated from NAMCS data and the lit-
erature [32]. All patients were assigned the cost of one
magnetic resonance imaging (MRI) scan. Resource use
and costs for relapse-related outpatient treatment for
physical therapy (PT), occupational therapy (OT) and
speech therapy (ST) were obtained from NAMCS data,
CMS data and the literature [14,15,27–29,32]. The unit
cost for an initial comprehensive medical assessment visit,
follow-up office visit with the usual care physician, and
consultation with specialists was established using the
appropriate CPT-4 code [38], the Medicare physician and
laboratory fee schedules for those ≥ 65 years and the
derived unit costs for those <65 years based on the meth-
odology described previously.
Medications
The daily cost of outpatient medications prescribed to
manage symptoms during a relapse episode (e.g.,
amitriptyline, baclofen) was included in the cost esti-
mates derived for each level of management. The propor-
tion of patients receiving medication to manage
symptoms during a relapse and the daily cost was esti-
mated from the literature and the 2001 Red
Book[5,30,39,40]. The cost of disease modifying drugs
such as interferon-β-1b (Betaseron), interferon-β-1a
(Avonex) and glatiramer acetate/copolymer 1 (glatiramer,
Copaxone) were considered to be ongoing management
costs and were excluded from the costs associated with a
relapse. Intravenous (IV) methylprednisolone followed
by a tapering dose of oral prednisone is used to treat acute
exacerbations [31,33,41]. The frequency of use of oral
steroids by those receiving infusions was determined from
the literature [31]. For those receiving inpatient manage-
ment, the cost of methylprednisolone infusions is
included in the hospital stay cost estimates, but as this
treatment is also administered in the outpatient setting,BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/17
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this therapy was included in the cost of the medium inten-
sity management level as well. The cost of administering
infusions at home was obtained from the literature [42].
A day case cost was derived by analyzing a subset of the
MS cases in the Massachusetts Observation Unit data set
that received steroids by infusion [25]. To identify these
cases, all the Observation Unit cases were screened for
ICD-9 procedure codes 99.25 (injection of steroid) and
99.29 (injection or infusion of other therapeutic or pro-
phylactic substance).
Cost Estimates
All cost estimates are reported in 2002 US dollars. Where
2002 values were not available, older estimates were
inflated using rates based on the medical care component
of the United States Consumer Price Index, supplied by
the Federal Bureau of Labor Statistics [43]. Any charges
used as inputs (e.g., inpatient hospital care) were adjusted
to costs using a cost-to-charge ratio. In the absence of a
standard value, a ratio of 0.61 was used, as this is the most
recent figure calculated by the Commonwealth of Massa-
chusetts Office of Health Care Finance and Policy for hos-
pitals in Massachusetts. Where single state databases were
used (e.g., ER, observation unit nursing home), state-spe-
cific costs were adjusted to national values using CMS geo-
graphical cost information [20].
Results
High Level
Data from the five state discharge databases revealed that
a diagnosis of MS was recorded for 17,743 cases, and as a
primary diagnosis in 3,421 (19%) cases. Based on the
study criteria, when MS was coded as a secondary diagno-
sis, only those cases with a principal diagnosis of a condi-
tion or symptom that could be associated with a relapse
were included in the analyses (1,213 cases). A total of
4,634 study-eligible cases were identified. The majority
(73%) was female. The mean age was 48 years, and 54%
of the cases were between the ages of 25 and 44 years.
Primary payer data revealed that managed care organiza-
tions (MCO) comprise the second largest payer category
for inpatient care. For this analysis, the MCO payer cate-
gory includes various types of non-Medicare and non-
Medicaid funded health care insurance plans including
health maintenance organizations (HMO), preferred pro-
vider organizations (PPO) and point of service plans
(POS) (Figure 2). Of note, although only 10% of patients
are > = 65 years, Medicare is the responsible payer for 39%
of the admissions and is the largest single payer. The high
proportion of Medicare patients with MS in this sample is
likely due to those who qualify for this type of coverage
due to a disability rather than age. The Medicare category
includes those covered under the traditional fee for service
Table 1: Mean unit costs by major cost categories. Overall costs are weighted average of component costs applied to the proportion of 
patients using the service. Thus, the individual components will not add up to the overall cost
Management level Cost component Unit Mean Unit Cost 2002 US $
Low Overall cost Per episode 243
Physician visits Per episode 170
Symptom-related medications Per episode 73
Medium Overall cost Per episode 1,847
ER visit Per visit 475
Observation unit Per stay 2,111
Initial office visit for acute problem with CBC, BMP Per visit 240
IV Methylprednisolone:
Day case Per episode 3,184
Home care Per episode 792
Symptom-related medications Per episode 73
Other diagnostic and laboratory tests Per episode 849
Therapies (i.e., PT, OT, ST) Per episode 207
High Overall cost Per episode 12,870
Acute hospital Per stay 8,782
Post-discharge Per episode 4,088
Rehabilitation facility Per stay 14,943
Skilled nursing facility Per stay 10,514
Short term nursing home Per stay 12,894
Home heath care services Per episode 2,043
Outpatient care Per episode 114
(Abbreviations: ER = emergency room, CBC= complete blood count, BMP=basic metabolic profile, PT = physical therapy, OT = occupational 
therapy, ST=speech therapy)BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/17
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plan (83%) and Medicare sponsored managed care plans
(17%).
The mean LOS for a hospital stay was 5.2 days (range: 1–
353) with a mean cost of $8,782 (range: $410–1,045,376)
when all cases are considered. If the study group is
restricted to those in hospital 90 days or less, we would
eliminate 15 cases (0.32%) and the mean cost would be
$8,392 (range:$420–302,545). As would be expected,
acute care hospitalization is the major cost component of
high-level management, accounting for 70% of the total
cost. From our analyses, half of all cases were admitted via
the ER. The patients who are seen in the ER prior to hos-
pitalization have a higher cost per stay ($9,076) on aver-
age than those referred to the hospital directly by their
physician ($8,183). Table 1 provides a summary of costs
by major cost category used in this analysis.
The inpatient case fatality rate was 1%. Of those who sur-
vived the hospitalization: 59% were discharged to home;
14% with home health care services (mean cost of $2,043
per relapse episode); 10% to inpatient rehabilitation
(mean LOS = 15 days, range: 1–126 days; mean cost per
stay $14,943, range: $645–$105,480); 11% to a skilled
nursing facility (mean LOS = 28 days, mean cost per stay
Distribution of multiple sclerosis cases from state databases by primary payer Figure 2
Medicare MCO Medicaid Com. Ins./BC Other
0
10
20
30
40
50
Emergency Room Observation Unit Inpatient
Figure 2 Distribution of multiple sclerosis cases from state databases by primary payer
(Abbreviations:  MCO-managed care organization; Com Ins.=commercial insurance; BC=Blue Cross)BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/17
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$10,514); and 1% to nursing home care (mean cost per 90
day stay $12,894, range: $7,709–$14,200). The costs of
these levels of care were applied proportionately to the
users of those services to derive the typical overall
weighted post-acute care cost. For the remaining 5%
(other), the disposition status was either unknown or was
a level of care (e.g., custodial residential care) that would
not be covered by third party payers in the US and is there-
fore not a direct medical cost relevant to this analysis. Of
those discharged initially to a rehabilitation facility or
unit, 1% died during their stay, 8% were transferred to a
skilled nursing facility, 38% required home health care
services after discharge and the remainder were followed
as outpatients.
For those discharged to home, follow-up outpatient care
consisted of one physician visit ($37), and the calculated
weighted average cost of symptom related medications
($73) for 90 days less the LOS in hospital. For patients
discharged from a SNF or inpatient rehabilitation, the cost
of an outpatient follow-up physician office visit care plus
a home assessment visit ($35) was added to the cost of
their sub-acute stay. In addition, the cost of symptom
related medications was added for the 90-day period
minus the number of days the patients was in acute and
sub-acute inpatient care. Furthermore, the cost of a repeat
hospitalization was included in the post-acute care esti-
mate for the 4% who were readmitted within 30 days of
discharge. When all post-acute care costs are weighted
proportionately by the percent of those who used them,
the typical post-discharge subsequent care cost per person
is estimated at $4,088 (potential range: $37–$24,382) per
person per 90-day relapse episode.
Thus, for patients who experience a relapse with symp-
toms severe enough to require hospitalization, the typical
cost for a relapse episode over 90-days is $12,870. Figure
3 provides an overview of the proportional contribution
of the major cost components to the typical cost for this
management level.
Medium Level
Separate resource use profiles were developed for those
who were initially seen in the ER versus those whose ini-
tial encounter was with their usual care physician at the
onset of symptoms. Based on 401 cases identified in the
ER database, of whom 76% were female and 44% were
between the ages of 25–44 years, the mean cost of an ER
visit for those discharged to outpatient care after the visit
was estimated at $475 (range: $30–$7,745). This cost
includes facility, ancillary and physician costs. The mean
time for an ER visit was 7 hours (range: 1–23 hours) and
a MCO was the responsible payer for 32% of the cases
(Figure 2).
Analysis of the Massachusetts Observation Unit database
resulted in identification of 369 study-relevant cases.
Females comprised 68% of the cases and the mean age
was 48 years. The mean observation time was 25.8 hours
(range: 1–90 hours) with a mean cost per stay of $2,111
(range:$23–$20,853). MCOs were the primary payer for
almost a third of the observation unit cases (Figure 2).
The cost of administering methylprednisolone IV (750 mg
per day over 8 hours for four days) was estimated both
when provided as a day case ($3,814) and home care
($792). The day case estimate was obtained by analyzing
30 cases attending Massachusetts Observation Units, who
received IV steroids. In the absence of published informa-
tion about the proportion of patients who receive infu-
sions as observed day cases versus in a home care setting
in the US, an assumption was made that 25% of the 56%
[31] of relapse patients who receive this therapy are
treated as day cases. The cost of a course of oral pred-
nisone was estimated at $3.33 and was applied to 21%
[31] of the patients receiving infusions. The cost of the ini-
tial comprehensive office visit with the patient's usual care
physician including basic laboratory tests was estimated at
$240. The proportions of patients receiving other tests on
follow-up were as follows: 11% urinalysis, 4% ultrasound
of bladder or bladder function studies, 2% spinal tap, and
2% electromyography. Based on information from
NAMCS the medium intensity cost for usual care physi-
cian follow-up and consults was derived based on 91%
returning for a follow-up office visit, 10% referred to a
urologist, 5% to an ophthalmologist and 12% to other
specialists. The weighted cost of these additional tests,
referrals and follow-up visits were applied to both the ER
and usual care physician profiles. In addition, the cost of
a course of outpatient physical ($1,117), speech ($681)
and occupational therapy ($1,240) was applied to 10%,
6% and 5% of patients respectively [5]. The cost of symp-
tom related medications was applied to 95% of the
patients [30] for 90 days to complete this profile.
For patients who see their usual care physician initially,
the typical cost for a relapse episode that required this
level of management was estimated to be $1,836, and
31% higher for patients whose symptoms were evaluated
initially in the ER ($2,408). This increase is due to the
incremental cost of the ER visit plus physician services
rendered in the ER for a serious but non-life threatening
condition and a follow-up visit to the patient's usual care
physician soon after the ER visit. Otherwise, the profiles
are identical. Based on NAMCS data analyses, just 2% of
the patients were initially seen in the ER, after weighting
these costs appropriately, a relapse episode with this
medium level of management costs $1,847, on average.
The low end of the range was estimated to be $316 for
those who do not receive IV methylprednisolone toBMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/17
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$12,525 when an ER visit is made followed by extensive
testing and multiple referrals. Figure 4 provides an over-
view of the proportional contribution of the major cost
components for the typical medium level management
cost.
Low Level
The overall cost of a relapse that receives a low intensity
level of management is estimated at $243 (range: $171–
$952) per person. The major cost component is the cost
of the initial office visit with the patient's usual care phy-
sician including basic lab tests for those who receive them.
Based on analyses of the NAMCS data 64% of patients
return for a follow-up visit. As for the other profiles, the
cost of medications to relieve symptoms during the
relapse episode was applied to 95% of the patients based
on information from the literature [30].
Discussion
Relapses and the progression of the disease with the devel-
opment of irreversible disability are two key clinical char-
acteristics of MS [3,44,45]. Acute exacerbations of MS are
commonly managed with infusions of steroids, such as
methylprednisolone administered in the out patient set-
ting [46]. In fact, some insurers now have criteria that
have to be met before a patient can be admitted overnight
for this type of therapy [47]. Yet, there remain some cases
where a relapse has to be managed intensively and
requires an admission to hospital, for example, when a
severe neurological deficit is present [47]. Previous studies
have shown that hospitalization remains a significant
Proportion of overall high-level management cost by major cost components Figure 3
70%
11%
2%
11%
3% 2% 1%
Hospital Stay
Rehabilitation
Pre-Admission Emergency Room
SNF Care
Short Stay Nursing Home Care
Home Health Care Services
Post-Discharge Outpt Follow-up
Figure 3 Proportion of overall high-level management cost by major cost components
(Abbreviations:  SNF=skilled nursing facility, Outpt=outpatient)BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/17
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component of the cost of managing MS [4,48], but as
practice patterns change there is an increased interest in
avoiding hospitalization where clinically prudent, such as
those due to bladder dysfunction by improving self care
[48] or by utilizing alternative sites of care, such as obser-
vation units or home care. Our study suggests that the cost
of managing a relapse will typically increase over six fold
if inpatient care is provided, compared with a relapse that
can be managed with IV steroids as an outpatient.
When assessing chronic clinical conditions in the US,
Medicare is often the payer of interest given the usual age
distribution of chronically ill patients; however, patients
diagnosed with MS are typically younger than 65 years
old, and so have insurance coverage from a variety of
health care service plans. As would be expected for
patients diagnosed with MS, most of the inpatient (90%)
and ER cases (93%) were younger than 65 years old. Even
so, Medicare was the primary payer for 39% of the inpa-
tient cases and 23% of ER cases. Managed care plans paid
for over a quarter of the inpatient cases (28%), and for
almost a third of the ER cases (32%). These figures are
consistent with a survey by the National Multiple Sclerosis
Society, which indicated that while Medicare insured the
majority of respondents, at least a quarter held private
insurance[4]. Given these figures, although Medicare does
Proportion of overall medium level management cost by major cost components Figure 4
IV Methylprednisolone Rx
Emergency Room Visit
Symptom-Related Meds
Non-ER MD Visits/Consults
Diagnostic and Lab Tests
Observation Unit Stays
Therapies (i.e., PT, OT, ST)
33%
1%
4%
15%
36%
10%
3%
Figure 4 Proportion of overall medium level management cost by major cost 
components
(Abbreviations: IV=intravenous, Rx=therapy, MD=medical doctor, 
PT=physical therapy, OT=occupational therapy, ST=speech therapy)BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/17
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have a larger than might be expected role in the coverage
for this younger group of patients, economic concerns
related to MS relapse management are likely to be equally
germane to MCOs.
Scarce information was found in the literature that could
shed light on the management cost of relapse in the US by
level of health care needs. Most of the published studies
from the US and elsewhere are cost of illness studies and
include indirect costs which for the most part combine all
types of MS into one group for reporting purposes so teas-
ing out the cost of managing a relapse is not possible [37].
Other published sources, often cited in reports about MS,
present information on studies that are not necessarily
representative of an MS "real world" populations. For
example, there are references in the literature to a health
care cost study done on veterans in the US [48]. While this
study provides valuable information, its relevance to the
MS population as a whole and a managed care population
in particular is questionable as 89% of the participants
were male and only 13% of the patients had relapsing-
remitting MS. Prevalence data of MS in the US show that
73% of those with the condition are female [37]. The
results of our data analysis support this in that the major-
ity of formal care seekers were female at all locations of
care in our study. This analysis, which uses an approach
heretofore not taken in calculating the cost of managing a
relapse, presents a detailed picture of possible manage-
ment scenarios for relapse in actual practice settings.
In this study, the cost profiles developed for inpatient
care, emergency room visits, nursing home stays and phy-
sician visits were all based on data collected from patients
with a recorded diagnosis of MS. MS has been allocated a
specific ICD-9 code, and this allowed selection of the
cases with multiple sclerosis from the various databases
used in these analyses. Unfortunately, the ICD-9 code did
not allow us to differentiate between cases with different
types of MS; therefore, it is unknown how many cases had
the relapsing-remitting or progressive forms of the dis-
ease. Cases were excluded where the admission or the visit
was primarily for depression or other mood disorders. In
this analysis, these were considered to be related more to
the consequences of living with multiple sclerosis than a
relapse [37].
A key cost component of the medium intensity manage-
ment level arises from administering a course of methyl-
prednisolone infusions in the out patient setting. As
would be expected, the cost estimated for home infusion
therapy is substantially lower, approximately one quarter
of the cost of providing this care as a hospital day case.
One important limitation of our study is that whilst these
are credible estimates of the cost of providing the infu-
sions in each setting, information about the proportion of
patients receiving these infusions as a day case was not
available to us. The overall cost estimate for the medium
management level assumed the minority (25%) receives
the infusions as a day case rather than home infusions,
and this is conservative based on known insurance
coverage restrictions [47] and personal communication
with staff of several US based MS clinics. It is also likely
that the portion of the costs contributed by testing is a
conservative estimate. The low rates of diagnostic and lab-
oratory tests noted in the NAMCS data may be more
reflective of under coding diagnostic tests than the level of
actual utilization.
The average wholesale price (AWP) was used as the basis
for estimating the outpatient symptom-related medica-
tion profile. Although the AWP is not representative of the
cost that most purchasers or users pay for a drug, it was
selected as the reference cost to provide a common, under-
standable baseline from which a comparison can be made
for a given circumstance. This approach was taken rather
than base the analysis on any one organization's dis-
counted rate; as such an estimate would not be represent-
ative past the environs of the selected organization.
It has been noted that patients with chronic illnesses
adapt to their level of disability and learn to accommo-
date changes in physical condition without seeking for-
mal care even when a symptom may be termed as
"bothersome"[32]. Thus, not every mild relapse will gen-
erate costs even at the low management level. Neverthe-
less, based on our analyses of the NAMCS data, once
patients attend their physician for an acute MS-related
problem, almost two-thirds will return for a follow-up
visit.
The development of disease modifying agents in recent
years has altered the clinical management of this illness.
The current health care environment requires decision-
makers to consider the fiscal, as well as the clinical conse-
quences of therapy (i.e. cost-effectiveness analyses) when
allocating limited health care dollars. The cost estimates
for a relapse episode based on escalating levels of manage-
ment presented in this paper provide valuable inputs for
decision-makers and researchers seeking to evaluate and
understand the economic, as well as the clinical implica-
tions of disease modifying drugs for MS.
Conclusions
This study provides decision-makers costs heretofore
unknown based on current management practices. This
analysis has shown that there is a cost to a relapse regard-
less of the level of management once formal care is
sought.BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/17
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Clearly and not surprisingly, site of care will affect the cost
of a relapse, even amongst those treated as outpatients.
For patients who are initially seen in the ER, the cost of the
medium level of management is estimated to increase by
almost a third when compared with those seen initially by
their physician. Policies or standardized protocols of care
that lead to an increase in the proportion of patients
receiving steroid infusions at home or in another ambula-
tory setting, or those that encourage attending their usual
care physician rather than visiting the ER when clinically
appropriate, would therefore have a substantial impact on
the overall cost estimated for a relapse episode.
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